The use of immunobiological monoclonal antibody-based drugs in nephrological practice

O.O. Melnyk


With various diseases of the kidneys, immunobiological monoclonal antibody-based therapy with a different mechanism of action is successfully used. These drugs include: rituximab (interaction with the CD20 receptor and elimination of B cells), eсulizumab (inhibition of C5 complement clea­vage), burosumab (blocking fibroblast growth factor 23), adalimumab (anti-tumor necrosis factor α agent), abatacept (blocks co-stimulation of T cells by binding to CD80), fresolimumab (neutralization of transforming growth factor β). These drugs are used for systemic kidney diseases, focal segmental glomerulosclerosis, lupus nephritis, membranous nephropathy, kidney transplantation.


kidney diseases; monoclonal antibodies; rituximab; eculizumab; burosumab; adalimumab; abatacept; fresolimumab


Von Behring E. Die Praktischen Ziele Der Blutserumtherapie: Und Die Immunisirungsmethoden Zum Zweck Der Gewinnung Von Heilserum (1892). Delhi, India: True World of Books; 2018. 79 p.

Lindsten J. Pysiology or medicine 1901-1921. London: World Scientific Publishing; 1999. 561 p.

Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity, 1975. J Immunol. 2005 Mar 1;174(5):2453-5.

Smith SL. Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord. 1996 Sep;6(3):109-19; quiz 120-1.

Ecker D, Jones S, Levine H. The therapeutic monoclonal antibody market. MAbs. 2015;7(1):9-14. doi: 10.4161/19420862.2015.989042.

Wang S. Advances in the production of human monoclonal antibodies. Antibo Techn Journ 2011;1:1-4.

Sheinfeld N. Adalimumab (Humira): a review. J Drugs Dermatol. 2003 Aug;2(4):375-7.

Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discovery. 2010;9(10):767-74. doi:10.1038/nrd3229.

Bernett MJ, Karki S, G Moore GL, et al. Engineering Fully Human Monoclonal Antibodies from Murine Variable Regions. J Mol Biol 2010;396(5):1474-1490. doi:10.1016/j.jmb.2009.12.046.

Ansar W, Ghosh S. Monoclonal Antibodies: A Tool in Clinical Research. Indian J Clin Med. 2013;4:9-21. doi: 10.4137/IJCM.S11968.

Li J, Zhu Z. Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin. 2010 Sep;31(9):1198-207. doi: 10.1038/aps.2010.120.

Reff ME, Hariharan K, Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control. 2002;9(2):152-66. doi:10.1177/107327480200900207.

Rodrigues ME, Costa AR, Henriques M, Azeredo J, Oliveira R. Technological progresses in monoclonal antibody production systems. Biotechnol Prog. 2010;26(2):332-351. doi: 10.1002/btpr.348.

Lin W, Kurosawa K, Murayama A, Kagaya E, Ohta K. B cell display-based one-step method to generate chimeric human IgG monoclonal antibodies. Nucleic Acids Res. 2011;39(3):e14. doi:10.1093/nar/gkq1122.

Mak TM, Hanson BJ, Tan YJ. Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades. Antiviral Res. 2014;107(1):76-83. doi: 10.1016/j.antiviral.2014.04.011.

Wang S. Advances in the production of human monoclonal antibodies. Antib Technol J. 2011;1:1-4.

Chandel P, Harikumar SL. Pharmaceutical monoclonal antibodies: Production, guidelines to cell engineering and applications. Int J Pharm Pharm Sci 2013; 5(2):13-20.

Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. MAbs 2010;2(3):256-265.

Bernett MJ, Karki S, G Moore GL, et al. Engineering Fully Human Monoclonal Antibodies from Murine Variable Regions. J Mol Biol 2010;396(5):1474-1490. doi:10.1016/j.jmb.2009.12.046.

Steinitz M. Production of Human Monoclonal Antibodies by the Epstein–Barr Virus Method. In: Steinitz M, editor. Human Monoclonal Antibodies. New York: Humana Press; 2014; 111-122 pp.

Medecigo M, Manoutcharian K, Vasilevko V, et al. Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries. J Neuroimmunol. 2010;223(1-2):104-114. doi: 10.1016/j.jneuroim.2010.03.023.

Solforosi L, Mancini N, Canducci F, et al. A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments. New Microbiol. 2012;35(3):289-294.

Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discovery. 2010;9(10):767-74. doi:10.1038/nrd3229.

Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M. ScFv antibody: Principles and clinical application. Clinical and Developmental Immunology. 2012;2012:ID 980250. doi: 10.1155/2012/980250.

Leget GA, Czuczman MS. Use of rituximab, the new FDAapproved antibody. Curr Opin Oncol. 1998;10(6):548-551.

Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001 Feb;40(2):205-11.

Turner-Stokes T, Lu TY, Ehrenstein MR, Giles I, Rahman A, Isenberg DA. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford). 2011 Aug;50(8):1401-8. doi: 10.1093/rheumatology/ker018.

Kado R, Sanders G, McCune WJ. Suppression of normal immune responses after treatment with rituximab. Curr Opin Rheumatol. 2016 May;28(3):251-8. doi: 10.1097/BOR.0000000000000272.

Seyfizadeh N, Seyfizadeh N, Hasenkamp J, Huerta-Yepez S. A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Crit Rev Oncol Hematol. 2016 Jan;97:275-90. doi: 10.1016/j.critrevonc.2015.09.001.

Ramanath V, Nistala R, Chaudhary K. Update on the role of rituximab in kidney diseases and transplant. Expert Opin Biol Ther. 2012 Feb;12(2):223-33. doi: 10.1517/14712598.2012.646984.

Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ, et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol. 2011 Jun;40(3):159-69. doi: 10.1007/s12016-010-8205-3.

Walters GD, Willis NS, Craig JC. Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol. 2010 Jun 24;11:12. doi: 10.1186/1471-2369-11-12. doi:10.1186/1471-2369-11-12.

Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. Ann Rheum Dis. 2015 Jun;74(6):1178-82. doi: 10.1136/annrheumdis-2014-206404.

Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32. doi: 10.1056/NEJMoa0909905.

Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012 Apr;51(4):634-43. doi: 10.1093/rheumatology/ker150.

Monti G, Galli M, Invernizzi F, et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM. 1995 Feb;88(2):115-26.

Garini G, Allegri L, Lannuzzella F, et al. HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Acta Biomed. 2007;78(1):51-9.

Zaja F, De Vita S, Russo D, et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum. 2002 Aug;46(8):2252-4; author reply 2254-5. doi: 10.1182/blood-2002-09-2856.

Roccatello D, Baldovino S, Rossi D, et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia Clin Rev Allergy Immunol. 2008 Feb;34(1):111-7. doi: 10.1007/s12016-007-8019-0.

Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica. 1999 Dec;84(12):1157-8.

Ronco P, Debiec H. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol. 2010 Apr;21(4):564-9. doi: 10.1681/ASN.2009121220.

Ruggenenti P, Cravedi P, Remuzzi G. Latest treatment strategies for membranous nephropathy. Expert Opin Pharmacother. 2007 Dec;8(18):3159-71. doi:10.1517/14656566.8.18.3159.

Cravedi P, Sghirlanzoni MC, Marasa M, Salerno A, Remuzzi G, Ruggenenti P. Efficacy and safety of Rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol. 2011;33(5):461-8. doi: 10.1159/000327611.

Ruggenenti P, Cravedi P, Sghirlanzoni MC, et al. Effects of Rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol. 2008 Nov;3(6):1652-9. doi: 10.2215/CJN.01730408.

Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012 Aug;23(8):1416-25. doi: 10.1681/ASN.2012020181.

van Husen M, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol. 2011 Jun;26(6):881-92. doi: 10.1007/s00467-010-1717-5.

Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008 Aug;23(8):1269-79. doi: 10.1007/s00467-008-0814-1.

Kamei K, Ito S, Nozu K, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009 Jul;24(7):1321-8. doi: 10.1007/s00467-009-1191-0.

Prytula A, Iijima K, Kamei K, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010 Mar;25(3):461-8. doi: 10.1007/s00467-009-1376-6.

Gulati A, Sinha A, Jordan SC, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010 Dec;5(12):2207-12. doi: 10.2215/CJN.03470410.

Fuchinoue S, Ishii Y, Sawada T, et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation. 2011 Apr 27;91(8):853-7. doi: 10.1097/TP.0b013e31820f08e8.

Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant. 2004 Jun;4(6):996-1001. doi:10.1111/j.1600-6143.2004.00454.x.

Imamura R, Ishiguro S, Shi Y, et al. ABO-incompatible kidney transplantation with anti-CD20 monoclonal antibodies, intravenous immunoglobulin and plasmapheresis without splenectomy: a case report. Xenotransplantation. 2006 Mar;13(2):133-5. doi: 10.1111/j.1399-3089.2006.00295.x.

Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant. 2004 Aug;4(8):1315-22. doi:10.1111/j.1600-6143.2004.00507.x.

Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant. 2005 Jan;5(1):145-8. doi:10.1111/j.1600-6143.2004.00653.x.

Toki D, Ishida H, Horita S, Setoguchi K, Yamaguchi Y, Tanabe K. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int. 2009 Apr;22(4):447-54. doi: 10.1111/j.1432-2277.2008.00821.x.

Davis J. Eculizumab. Am J Health Syst Pharm. 2008 Sep 1;65(17):1609-15. doi: 10.2146/ajhp080043.

Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007 Nov;25(11):1256-64. doi:10.1038/nbt1344.

Scheiring J, Rosales A, Zimmerhackl LB. Clinical practice: today’s understanding of the haemolytic uraemic syndrome. Eur J Pediatr. 2010 Jan;169(1):7-13. doi: 10.1007/s00431-009-1039-4.

Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011 Jan;26(1):41-57. doi: 10.1007/s00467-010-1556-4.

Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009 Jan 29;360(5):544-6. doi: 10.1056/NEJMc0809959.

Lapeyraque A, Frémeaux-Bacchi V, Robitaille P. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011 Apr;26(4):621-4. doi: 10.1007/s00467-010-1719-3.

Davin J, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis. 2010 Apr;55(4):708-11. doi: 10.1053/j.ajkd.2009.08.011.

FDA. FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia (Press release). Available from: Accessed: 17 April, 2018.

Klinkhoff A. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs. 2004;64(12):1267-83.

D’Agati VD. Renal disease in systemic lupus erythematosus, mixed connective tissue disease, Sjogren’s syndrome, and rheumatoid arthritis. In: Jennette JC, Olsen JL, Schwartz MM, et al, eds. Heptinstall’s Pathology of the Kidney, vol 1. Lippincott-Raven, PA: 1998; 541-624 pp.

Hueber AJ, Tunc A, Schett G, Manger B. Anti-tumour necrosis factor _ therapy in patients with impaired renal function. Ann Rheum Dis. 2007 Jul;66(7):981-2. doi:10.1136/ard.2006.069211.

Cho SK, Sung YK, Park S, Bae SC. Etanercept treatment in rheumatoid arthritis patients with chronic kidney failure on predialysis. Rheumatol Int. 2010 Sep;30(11):1519-22. doi: 10.1007/s00296-009-1108-z.

Kobak S. Efficacy and safety of adalimumab in a patient with ankylosing spondylitis on peritoneal dialysis. Rheumatol Int. 2012 Jun;32(6):1785-7. doi: 10.1007/s00296-010-1457-7.

Hammoudeh M. Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology (Oxford). 2006 Mar;45(3):357-9. doi:10.1093/rheumatology/kei264.

Joy MS, Gipson DS, Powell L, et al. Phase 1 trial of adalimumab in focal segmental glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010 Jan;55(1):50-60. doi: 10.1053/j.ajkd.2009.08.019.

Bristol-Myers Squibb. Important Safety Information for ORENCIA® (abatacept). Available from: Accessed: Mar, 2018.

Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol. 2002 Feb;13(2):559-75.

Ostor AJ. Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. Clin Rheumatol. 2008 Nov;27(11):1343-53. doi: 10.1007/s10067-008-0964-3.

Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013 Dec 19;369(25):2416-23. doi: 10.1056/NEJMoa1304572.

Dennler S, Goumans MJ, ten Dijke P. Transforming growth factor beta signal transduction. J Leukoc Biol. 2002 May;71(5):731-40.

Yu L, Border WA, Huang Y, Noble NA. TGF-beta isoforms in renal fibrogenesis. Kidney Int. 2003 Sep;64(3):844-56. doi:10.1046/j.1523-1755.2003.00162.x.

Trachtman H, Fervenza FC, Gipson DS, et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-b antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 2011 Jun;79(11):1236-43. doi: 10.1038/ki.2011.33.

Vincenti F, Fervenza F, Campbell K, et al. A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis. Kidney Int Rep. 2017 Apr 7;2(5):800-810. doi: 10.1016/j.ekir.2017.03.011.

Trachtman H, Goyal S, Finn P, et al. Neutralizing TGF-b in fibrotic renal disorders: focus on fresolimumab. Drugs Future. 2012;37(11):787-794. doi: 10.1358/dof.2012.037.011.1888927.

Dorner T, Shock A, Smith KG. CD22 and autoimmune disease. Int Rev Immunol. 2012 Oct;31(5):363-78. doi: 10.3109/08830185.2012.709890.

Copyright (c) 2018 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© "Publishing House "Zaslavsky", 1997-2019


   Seo анализ сайта